CRISPR-hfCas12Max Genome Editing Therapy Demonstrates Preclinical Efficacy and Early Clinical Benefit in Duchenne Muscular Dystrophy
文献类型：期刊论文
| 作者 | Luk, Alvin9; Lin, Jiajia8; Jin, Ming7; Li, Zhifang6; Li, Tong5; Cradick, T. J.1,4; Yuan, Yiqun5; Zhang, Xin4,5; Shi, Linyu5; Yang, Hui2,5 |
| 刊名 | MOLECULAR THERAPY
 |
| 出版日期 | 2025-04-28 |
| 卷号 | 33期号:4页码:3 |
| ISSN号 | 1525-0016 |
| WOS研究方向 | Biotechnology & Applied Microbiology ; Genetics & Heredity ; Research & Experimental Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:001493880500002 |
| 出版者 | CELL PRESS |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/321111]  |
| 专题 | 中国科学院上海药物研究所 |
| 作者单位 | 1.Cholgene Therapeut, Middletown, DE USA 2.Chinese Acad Sci, Shanghai Inst Meteria Med, Shanghai, Peoples R China 3.Cholgene Therapeut, Middletown, NJ USA 4.HuidaGene Therapeut, Clinton, NJ USA 5.HuidaGene Therapeut Co Ltd, Shanghai, Peoples R China 6.Lin Gang Lab, Shanghai, Peoples R China 7.Fujian Med Univ, Fujian, Peoples R China 8.Fujian Med Univ, Affiliated Hosp 1, Dept Neurol, Fuzhou, Peoples R China 9.Huidagene Therapeut Inc, Clinton, NJ USA |
| 推荐引用方式 GB/T 7714 | Luk, Alvin,Lin, Jiajia,Jin, Ming,et al. CRISPR-hfCas12Max Genome Editing Therapy Demonstrates Preclinical Efficacy and Early Clinical Benefit in Duchenne Muscular Dystrophy[J]. MOLECULAR THERAPY,2025,33(4):3. |
| APA | Luk, Alvin.,Lin, Jiajia.,Jin, Ming.,Li, Zhifang.,Li, Tong.,...&Li, Guoling.(2025).CRISPR-hfCas12Max Genome Editing Therapy Demonstrates Preclinical Efficacy and Early Clinical Benefit in Duchenne Muscular Dystrophy.MOLECULAR THERAPY,33(4),3. |
| MLA | Luk, Alvin,et al."CRISPR-hfCas12Max Genome Editing Therapy Demonstrates Preclinical Efficacy and Early Clinical Benefit in Duchenne Muscular Dystrophy".MOLECULAR THERAPY 33.4(2025):3. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。